PTC Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $39.31
- Today's High:
- $40.48
- Open Price:
- $40
- 52W Low:
- $33.25
- 52W High:
- $59.84
- Prev. Close:
- $40.19
- Volume:
- 319830
Company Statistics
- Market Cap.:
- $3.03 billion
- Book Value:
- -7.691
- Revenue TTM:
- $818.73 million
- Operating Margin TTM:
- -58.5%
- Gross Profit TTM:
- $2.63 million
- Profit Margin:
- -75.49%
- Return on Assets TTM:
- -19.05%
- Return on Equity TTM:
- -7740.12%
Company Profile
PTC Therapeutics Inc had its IPO on 2013-06-20 under the ticker symbol PTCT.
The company operates in the Healthcare sector and Biotechnology industry. PTC Therapeutics Inc has a staff strength of 1,402 employees.
Stock update
Shares of PTC Therapeutics Inc opened at $40 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $39.31 - $40.48, and closed at $40.38.
This is a +0.47% increase from the previous day's closing price.
A total volume of 319,830 shares were traded at the close of the day’s session.
In the last one week, shares of PTC Therapeutics Inc have increased by +0.75%.
PTC Therapeutics Inc's Key Ratios
PTC Therapeutics Inc has a market cap of $3.03 billion, indicating a price to book ratio of 1743.2734 and a price to sales ratio of 4.0332.
In the last 12-months PTC Therapeutics Inc’s revenue was $818.73 million with a gross profit of $2.63 million and an EBITDA of $-311768992. The EBITDA ratio measures PTC Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, PTC Therapeutics Inc’s operating margin was -58.5% while its return on assets stood at -19.05% with a return of equity of -7740.12%.
In Q2, PTC Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 29.2%.
PTC Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0.81
Its diluted EPS in the last 12-months stands at $-8.26 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0.81. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into PTC Therapeutics Inc’s profitability.
PTC Therapeutics Inc stock is trading at a EV to sales ratio of 4.1773 and a EV to EBITDA ratio of -8.5903. Its price to sales ratio in the trailing 12-months stood at 4.0332.
PTC Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.34 billion
- Total Liabilities
- $476.34 million
- Operating Cash Flow
- $-23752000.00
- Capital Expenditure
- $19.28 million
- Dividend Payout Ratio
- 0%
PTC Therapeutics Inc ended 2024 with $1.34 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.34 billion while shareholder equity stood at $-579268000.00.
PTC Therapeutics Inc ended 2024 with $51.93 million in deferred long-term liabilities, $476.34 million in other current liabilities, 75000.00 in common stock, $-2994816000.00 in retained earnings and $82.34 million in goodwill. Its cash balance stood at $208.39 million and cash and short-term investments were $337.94 million. The company’s total short-term debt was $12,429,000 while long-term debt stood at $572.64 million.
PTC Therapeutics Inc’s total current assets stands at $589.69 million while long-term investments were $0 and short-term investments were $129.55 million. Its net receivables were $177.50 million compared to accounts payable of $25.74 million and inventory worth $32.02 million.
In 2024, PTC Therapeutics Inc's operating cash flow was $-23752000.00 while its capital expenditure stood at $19.28 million.
Comparatively, PTC Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $40.38
- 52-Week High
- $59.84
- 52-Week Low
- $33.25
- Analyst Target Price
- $52.13
PTC Therapeutics Inc stock is currently trading at $40.38 per share. It touched a 52-week high of $59.84 and a 52-week low of $59.84. Analysts tracking the stock have a 12-month average target price of $52.13.
Its 50-day moving average was $40.06 and 200-day moving average was $44.42 The short ratio stood at 10.52 indicating a short percent outstanding of 0%.
Around 260.8% of the company’s stock are held by insiders while 10783.7% are held by institutions.
Frequently Asked Questions About PTC Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company’s splicing platform includes PTC518, which is being developed for the treatment of Huntington’s disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.